PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
STOK vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between STOK and LLY is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

STOK vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Stoke Therapeutics, Inc. (STOK) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

-40.00%-30.00%-20.00%-10.00%0.00%10.00%SeptemberOctoberNovemberDecember2025February
-40.45%
-7.99%
STOK
LLY

Key characteristics

Sharpe Ratio

STOK:

0.53

LLY:

0.53

Sortino Ratio

STOK:

1.77

LLY:

0.94

Omega Ratio

STOK:

1.20

LLY:

1.12

Calmar Ratio

STOK:

0.59

LLY:

0.67

Martin Ratio

STOK:

2.17

LLY:

1.55

Ulcer Index

STOK:

25.23%

LLY:

10.54%

Daily Std Dev

STOK:

102.90%

LLY:

30.86%

Max Drawdown

STOK:

-95.17%

LLY:

-68.27%

Current Drawdown

STOK:

-88.07%

LLY:

-8.69%

Fundamentals

Market Cap

STOK:

$441.22M

LLY:

$784.71B

EPS

STOK:

-$2.08

LLY:

$11.70

Total Revenue (TTM)

STOK:

$13.94M

LLY:

$45.04B

Gross Profit (TTM)

STOK:

$10.61M

LLY:

$36.76B

EBITDA (TTM)

STOK:

-$86.61M

LLY:

$15.63B

Returns By Period

In the year-to-date period, STOK achieves a -24.48% return, which is significantly lower than LLY's 13.37% return.


STOK

YTD

-24.48%

1M

-16.87%

6M

-40.46%

1Y

56.58%

5Y*

-21.26%

10Y*

N/A

LLY

YTD

13.37%

1M

16.08%

6M

-7.99%

1Y

14.26%

5Y*

45.71%

10Y*

31.03%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

STOK vs. LLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

STOK
The Risk-Adjusted Performance Rank of STOK is 7070
Overall Rank
The Sharpe Ratio Rank of STOK is 6565
Sharpe Ratio Rank
The Sortino Ratio Rank of STOK is 7676
Sortino Ratio Rank
The Omega Ratio Rank of STOK is 7171
Omega Ratio Rank
The Calmar Ratio Rank of STOK is 7070
Calmar Ratio Rank
The Martin Ratio Rank of STOK is 6868
Martin Ratio Rank

LLY
The Risk-Adjusted Performance Rank of LLY is 6363
Overall Rank
The Sharpe Ratio Rank of LLY is 6565
Sharpe Ratio Rank
The Sortino Ratio Rank of LLY is 5858
Sortino Ratio Rank
The Omega Ratio Rank of LLY is 5757
Omega Ratio Rank
The Calmar Ratio Rank of LLY is 7373
Calmar Ratio Rank
The Martin Ratio Rank of LLY is 6464
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

STOK vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Stoke Therapeutics, Inc. (STOK) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for STOK, currently valued at 0.53, compared to the broader market-2.000.002.000.530.53
The chart of Sortino ratio for STOK, currently valued at 1.77, compared to the broader market-4.00-2.000.002.004.006.001.770.94
The chart of Omega ratio for STOK, currently valued at 1.20, compared to the broader market0.501.001.502.001.201.12
The chart of Calmar ratio for STOK, currently valued at 0.59, compared to the broader market0.002.004.006.000.590.67
The chart of Martin ratio for STOK, currently valued at 2.17, compared to the broader market-10.000.0010.0020.0030.002.171.55
STOK
LLY

The current STOK Sharpe Ratio is 0.53, which is comparable to the LLY Sharpe Ratio of 0.53. The chart below compares the historical Sharpe Ratios of STOK and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.501.001.502.002.50SeptemberOctoberNovemberDecember2025February
0.53
0.53
STOK
LLY

Dividends

STOK vs. LLY - Dividend Comparison

STOK has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.62%.


TTM20242023202220212020201920182017201620152014
STOK
Stoke Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.62%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%

Drawdowns

STOK vs. LLY - Drawdown Comparison

The maximum STOK drawdown since its inception was -95.17%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for STOK and LLY. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-88.07%
-8.69%
STOK
LLY

Volatility

STOK vs. LLY - Volatility Comparison

Stoke Therapeutics, Inc. (STOK) has a higher volatility of 26.20% compared to Eli Lilly and Company (LLY) at 7.16%. This indicates that STOK's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%SeptemberOctoberNovemberDecember2025February
26.20%
7.16%
STOK
LLY

Financials

STOK vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Stoke Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab